Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Despite the fact that the majority of the patients with limited disease SCLC will respond
very well to the standard treatment, a great proportion will relapse within 12 - 24 months.
Several studies in patients with lung cancer suggested a possible favourable association
between the increased presence of immunologically active cells in the tumour and survival.
Nivolumab and ipilimumab are proteins, which help your immune system to attack and destroy
cancer cells by your immune cells. Early clinical trials with nivolumab and ipilimumab have
shown activity in a broad range of cancers, including SCLC.
The aim of the current study is to investigate the efficacy (how well the treatment works)
and tolerability (how severe the side effects are) of the standard treatment (chemotherapy
and radiotherapy) alone, compared with the standard treatment followed by nivolumab and
ipilimumab in patients with limited SCLC.
Phase:
Phase 2
Details
Lead Sponsor:
European Thoracic Oncology Platform
Collaborators:
Bristol-Myers Squibb Frontier Science Foundation, Hellas Intergroupe Francophone de Cancerologie Thoracique Ludwig Center for Cancer Research of Lausanne